Analyst Price Targets — QTRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 20, 2026 1:02 pm | — | Canaccord Genuity | $4.00 | $3.33 | TheFly | Quanterix price target lowered to $4 from $8 at Canaccord |
| December 22, 2025 12:00 pm | — | Canaccord Genuity | $8.00 | $6.59 | TheFly | Quanterix price target raised to $8 from $5 at Canaccord |
| March 25, 2025 1:35 pm | Sung Ji Nam | Scotiabank | $18.00 | $7.02 | TheFly | Quanterix price target lowered to $18 from $28 at Scotiabank |
| June 11, 2024 7:54 am | Sung Niam | Scotiabank | $32.00 | $18.50 | StreetInsider | Scotiabank Reiterates Sector Outperform Rating on Quanterix Corp. (QTRX) |
| May 8, 2024 1:42 pm | Kyle Mikson | Canaccord Genuity | $25.00 | $16.51 | TheFly | Quanterix growth potential not reflected in shares, says Canaccord |
| November 10, 2022 10:12 am | — | Goldman Sachs | $13.00 | $11.72 | Benzinga | Goldman Sachs Maintains Neutral on Quanterix, Lowers Price Target to $13 |
Latest News for QTRX
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer's testing. Together, these milestones reinforce the growing role of LucentAD® Complete, Quanterix's five-analyte ATN(I) algorithmic blood test, in helping clinicians evaluate…
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on June 15, 2026, inducement grants (the “Inducement Grants”) were made to three employees in connection with the commencement of their employment. The Inducement Grants consisted of…
Quanterix Corporation (QTRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Jason Faessler as the Company's new Chief Financial Officer, effective June 22. Faessler brings extensive finance leadership experience and expertise in managing complex organizations in the life science…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for QTRX.
U.S. House Trading
No House trades found for QTRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.